The Efficacy of Infliximab plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5-Year Extended Study

Title: The Efficacy of Infliximab plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5-Year Extended Study

Author: Dr Niaz Al-Barzinji

DOI: http://dx.doi.org/10.18535/jmscr/v4i10.20

Abstract

Objective: To evaluate the role of infliximab plus methotrexate given for up to 5 years in patients with active longstanding rheumatoid arthritis.

Methods: patients responding inadequately to methotrexate and at least one other disease-modifying anti-rheumatic drug were enrolled into a 24 week, controlled study with infliximab plus methotrexate or placebo plus methotrexate and some were enrolled in a subsequent open label extension. The efficacy were evaluated.

Results: Among 250 patients in the original trial, 220 received at least one dose of infliximab and were evaluated. At the time of analysis 160/ 220 (72.7%) patients had remained in the study and received treatment for a mean of 4.5 years. Withdrawals were for lack of efficacy (24%), adverse events (36%), and other reasons(50%). In 160 patients who completed 5 years treatment efficacy achieved of 6 month was maintained at 5 years. 45% achieved clinical remission (DAS28<2.6), and 27% had no physical function abnormalities (HAQ=0). Results were similar for 160 patients who received treatment for 3-5 years.

Conclusions: Infliximab plus methotrexate sustained clinical response and remission in patients with rheumatoid arthritis during 5 years

References

1. Choy E, Panayi G. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344:907-16.

2. Lee D, Weinblatt M. Rheumatoid arthritis. Lancet 2001; 358:903-11.

3. O'Dell J. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004; 350:2591-602.

4. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmesler GR, Bijlsma JW, et al. Updated concensus statement on biolo-gical agents, specifically tumor necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonists (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005; 64(suppl IV): iv 2-14.

5. Lipsky P, van der heijde D, St Clair E, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy group. N Engl J Med 2000; 343:1594-602.

6. Arnett F, Edwarthy S, Bloch D, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.

7. Prevoo M, van T Hof M, Kuper H, van Leeuwent, M, van de Putte L, Riel P. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8.

8. Prevoo M, van T Hof M, van Gestel A, van Rijiswik M, van de Putte L, Riel P. Remission in a prospective study of patients with rheumatoid arthritis. Ameri-can Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatolo 1996;35: 1101-5.

9. Kremer J, Weinblatt M, Bankhurst A, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis. Continued observ-ation. Arthritis Rheum 2003;6;1493-9.

10. Weinblatt M. Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 2003;63(suppl 2): 1194-6.

11. Wolfe F, Rehman Q, Lane N, Kremer J. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment. J Rheumatol 2001;28:1704-11

12. Lambert C, Sandhu S, Lachhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate. A randomized, controlled trial. Arthritis Rheum 2004;50:364-71.

13. O'Dell J, Haire C, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulasalazine and hydroxychloroq-uine or a combination of all three medica-tions. N Engl J Med 1996;334:1287-91.

14. Keystone E, Kavanaugh A, Sharp J, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical and functional outcomes of treatment with adalimimab ( a human anti-tumor necrosis factor monoc-lonal antibody). in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004;50:1400-11.

15. Maini R, Breeveld F, Kalden J, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50:1051-65.

16. St Clair E, Desiree M, van der Heijda D, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotre-xate therapy for early rheumatoid arthritis. Arthritis Rheum 2004;50:3432-43.

17. Weinblall M, Kremer J, Bankhurst A, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.

18. Klareskog L, van der Heijda D, de Jager J, Gough A, Kalden A, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomized controlled trial. Lancet 2004;363:675-81.

19. Genovese M, Bathon J, Martin R, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two years radiographical and clinical out-comes. Arthritis Rheum 2002;46:1443-50.

20. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.

21. Felson DT, Edwarthy S, Bloch D, McShane DJ, Fries JF, Cooper NS, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.

22. Lubeck D. Health-related quality of life measurements and studies in rheumatoid arthritis. Am J Manag Care 2002;8:811-20.

23. Surveillance, Epidemiology and End Results (SEER) Program Public-Use Data Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission.

24. Balsa A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tena X, Sammarti R. Value of disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004;31:40-6.

25. Goldsmith CH, Boers M, Bambardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol 1993;20:561-5.

26. Breedveld F, Han C, Bala M, van der Heijda D, Baker D, Kavanaugh AF, et al. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:52-5.

27. Doran M, Crowson C, Pond G, O'Fallon W, Gabriel S. Frequency of infection in patients with rheumatoid arthritis compare-ed with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.

Corresponding Author

Dr Niaz Al-Barzinji

Consultant Rheumatologist

Iraq- Erbil

Hawler Medical University/College of Medicine